Article

IOL filters, protects against harmful UV, blue-light hazard

Author(s):

Lynda Charters

London-Exposure of the retina to excessive blue light is hazardous to the pigment epithelial cells and may underlie the increase in the prevalence of age-related macular degeneration (AMD) in individuals in the eighth and ninth decades of life.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Related Content
(Image credit: AdobeStock/iQoncept) Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
July 23rd 2025

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%
July 3rd 2025

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

ForSight Robotics completes $125M Series B funding to address global surgeon shortage
June 25th 2025

ForSight Robotics completes $125M Series B funding to address global surgeon shortage

(Image courtesy of New York Eye and Ear Infirmary of Mount Sinai) Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE
June 23rd 2025

Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE

© 2025 MJH Life Sciences

All rights reserved.